use of tumor markers in testicular, prostate, colorectal, breast, and ...

68 Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
231. Davies RJ, Miller R, Coleman N. Colorectal cancer screening:
prospects for molecular stool analysis. Nat Rev Cancer
2005;5:199–209.
232. Sobin LH WCe. TNM: Classification of malignant tumors. 6th.
ed. New York, NY: Wiley-Liss, 2002.
233. Greene FL, Oage DL, Fleming ID, Fritz ID, Balch CM, Haller
DG, et al. AJCC (American Joint Comittee on Cancer) Cancer
Staging Manual. New York: Springer-Verlag, 2002.
234. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP.
American Joint Committee on Cancer Prognostic Factors
Consensus Conference: Colorectal Working Group. Cancer 2000;
88:1739–1757.
235. NIH Consensus Conference. Adjuvant therapy for patients with
colon and rectal cancer. JAMA 1990;264:1444–1450.
236. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller
DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy
for stage II and III colon cancer: who benefits and by how
much? J Clin Oncol 2004;22:1797–1806.
237. Benson AB, III, Schrag D, Somerfield MR, Cohen AM,
Figueredo AT, Flynn PJ, et al. American Society of Clinical
Oncology recommendations on adjuvant chemotherapy for stage
II colon cancer. J Clin Oncol 2004;22:3408–3419.
238. Kievit J. Follow-up of patients with colorectal cancer: numbers
needed to test and treat. Eur J Cancer 2002;38:986–999.
239. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med
1986;104:66–73.
240. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal
cancer: is it clinically useful? Clin Chem 2001;47:624–630.
241. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the
staging and follow-up of patients with colorectal cancer. Cancer
Invest 2005;23:338–351.
242. Clinical practice guidelines for the use of tumor markers in
breast and colorectal cancer. Adopted on May 17, 1996 by the
American Society of Clinical Oncology. J Clin Oncol 1996;
14:2843–2877.
243. Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup
JM, et al. 2000 update of recommendations for the use of tumor
markers in breast and colorectal cancer: clinical practice guidelines
of the American Society of Clinical Oncology. J Clin Oncol
2001;19:1865–1878.
244. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N,
Macdonald JS, et al. ASCO 2006 update of recommendations
for the use of tumor markers in gastrointestinal cancer. J Clin
Oncol 2006;24:5313–5327.
245. Klapdor R, Aronsson AC, Duffy MJ, Hansson LO, Khalifa R,
Lamerz R, et al. Tumor markers in gastrointestinal cancers:
EGTM recommendations. Anticancer Res 1999;119:2811–2815.
246. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R,
Lamerz R, et al. Clinical utility of biochemical markers in colorectal
cancer: European Group on Tumour Markers (EGTM)
guidelines. Eur J Cancer 2003;39:718–727.
247. Grem J. The prognostic importance of tumor markers in adenocarcinomas
of the gastrointestinal tract. Curr Opin Oncol
1997;9:380–387.
248. Watine J, Miedouge M, Friedberg B. Carcinoembryonic antigen
as an independent prognostic factor of recurrence and survival
in patients resected for colorectal liver metastases: a systematic
review. Dis Colon Rectum 2001;44:1791–1799.
249. Watine J, Friedberg B. Laboratory variables and stratification of
metastatic colorectal cancer patients: recommendations for therapeutic
trials and for clinical practice guidelines. Clin Chim Acta
2004;345:1–15.
250. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS,
Hamilton SR, et al. Prognostic factors in colorectal cancer.
College of American Pathologists Consensus Statement 1999.
Arch Pathol Lab Med 2000;124:979–994.
251. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC,
Habbema JD, van de Velde CH. Follow-up of patients with colorectal
cancer. A meta-analysis. Ann Surg 1994;219:174–182.
252. Rosen M, Chan L, Beart RW, Jr., Vukasin P, Anthone G. Followup
of colorectal cancer: a meta-analysis. Dis Colon Rectum
1998;41:1116–1126.
253. Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on
survival of intensive follow up after curative resection for colorectal
cancer: systematic review and meta-analysis of randomised
trials. BMJ 2002;324:813–820.
254. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B,
McLeod R, et al. Follow-up of patients with curatively resected
colorectal cancer: a practice guideline. BMC Cancer 2003;
3:26–38.
255. Jeffrey GM, Hickey BE. Follow-up strategies for patients treated
for nonmetastatic colorectal cancer (Cochrane Review). The
Cochrane Library. Vol. Chichester, UK: John Wiley & Sons Ltd.,
2004.
256. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal
cancer: a meta-analysis. Dis Colon Rectum 2007;
50:1783–1799.
257. Desch CE, Benson AB, 3rd, Somerfield MR, Flynn PJ, Krause
C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005
update of an American Society of Clinical Oncology practice
guideline. J Clin Oncol 2005;23:8512–8519.
258. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson
RW, et al. Modulation of fluorouracil by leucovorin in patients
with advanced colorectal cancer: an updated meta-analysis. J
Clin Oncol 2004;22:3766–3775.
259. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer.
N Engl J Med 2005;352:476–487.
260. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival
and disease-progression benefits with treatment regimens for
advanced colorectal cancer: a meta-analysis. Lancet Oncol
2007;8:898–911.
261. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a
review. Ann Clin Biochem 1998;35 (Pt 3):364–370.
262. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H,
Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic
accuracy in gastrointestinal cancers. Anticancer Res
2002;22:2311–2316.
263. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H,
Jarvinen H, Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and
hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour
Biol 2004;25:228–234.
264. Lindmark G, Bergstrom R, Pahlman L, Glimelius B. The association
of preoperative serum tumour markers with Dukes’ stage
and survival in colorectal cancer. Br J Cancer 1995;71:1090–1094.
265. Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as
a predictor of recurrence in patients with colorectal cancer. J
Surg Oncol 1997;66:238–243.
266. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz
R. Multivariate analysis of the prognostic value of CEA and CA
19-9 serum levels in colorectal cancer. Anticancer Res
2000;20:5195–5198.
267. Behbehani AI, Al-Sayer H, Farghaly M, Kanawati N, Mathew A,
al-Bader A, van DA. Prognostic significance of CEA and CA 19-
9 in colorectal cancer in Kuwait. Int J Biol Markers 2000;15:51–55.